Absci Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Absci Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.53M | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | $5.72M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $5.75M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $4.78M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $4.78M | Mar 22, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($115.18M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($103.11M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($110.57M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($104.90M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($100.96M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($14.35M) | Mar 22, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($120.32M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($108.89M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($115.52M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($106.75M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($75.24M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($13.30M) | Mar 22, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.42M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $63.86M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $48.07M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $58.91M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $44.59M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $11.45M | Mar 22, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.06M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $36.17M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $37.83M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $40.55M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $28.78M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.50M | Mar 22, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($92.93M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($72.40M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($64.64M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($81.34M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($60.60M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.97M) | Mar 22, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.11M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $404.0K | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $860.0K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $16.18M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $38.05M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.18M | Mar 22, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.30M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $213.61M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $217.30M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $321.01M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $426.20M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $88.57M | Mar 22, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.85M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $34.48M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $41.12M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $46.59M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $60.09M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $21.56M | Mar 22, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $189.45M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $179.13M | Mar 24, 2026 |
| FY2025 | Dec 31, 2023 | $176.18M | Mar 24, 2026 |
| FY2024 | Dec 31, 2022 | $274.41M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $366.11M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | ($89.43M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($41.16M) | Mar 22, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | $21.34M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $21.34M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 22, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($624.78M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($509.60M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($406.50M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($295.93M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($191.03M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($90.07M) | Mar 22, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.03M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $41.21M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $72.36M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $59.96M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $252.57M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $69.87M | Mar 22, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.99M | Mar 18, 2025 |
| FY2023 | Dec 31, 2023 | $7.92M | Mar 21, 2024 |
| FY2022 | Dec 31, 2022 | $10.93M | Mar 30, 2023 |
| FY2021 | Dec 31, 2021 | $3.52M | Mar 22, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 22, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 22, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 115.36M | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | 93.09M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 92.41M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 92.65M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 17.89M | Mar 22, 2022 |